Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ANIK's Cash to Debt is ranked higher than
97% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ANIK: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANIK' s 10-Year Cash to Debt Range
Min: 1.5  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ANIK's Equity to Asset is ranked higher than
88% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ANIK: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ANIK' s 10-Year Equity to Asset Range
Min: 0.49  Med: 0.77 Max: 0.94
Current: 0.92
0.49
0.94
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
94% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANIK' s 10-Year Interest Coverage Range
Min: 38.66  Med: 10000.00 Max: 9999.99
Current: No Debt
38.66
9999.99
F-Score: 6
Z-Score: 21.93
M-Score: -2.68
WACC vs ROIC
19.46%
36.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 49.46
ANIK's Operating margin (%) is ranked higher than
96% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ANIK: 49.46 )
Ranked among companies with meaningful Operating margin (%) only.
ANIK' s 10-Year Operating margin (%) Range
Min: -65.51  Med: 16.66 Max: 58.19
Current: 49.46
-65.51
58.19
Net-margin (%) 30.77
ANIK's Net-margin (%) is ranked higher than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ANIK: 30.77 )
Ranked among companies with meaningful Net-margin (%) only.
ANIK' s 10-Year Net-margin (%) Range
Min: -60.87  Med: 11.61 Max: 42.28
Current: 30.77
-60.87
42.28
ROE (%) 15.79
ANIK's ROE (%) is ranked higher than
89% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. ANIK: 15.79 )
Ranked among companies with meaningful ROE (%) only.
ANIK' s 10-Year ROE (%) Range
Min: -44.09  Med: 9.41 Max: 46.29
Current: 15.79
-44.09
46.29
ROA (%) 14.41
ANIK's ROA (%) is ranked higher than
92% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. ANIK: 14.41 )
Ranked among companies with meaningful ROA (%) only.
ANIK' s 10-Year ROA (%) Range
Min: -33.73  Med: 6.47 Max: 27.49
Current: 14.41
-33.73
27.49
ROC (Joel Greenblatt) (%) 73.04
ANIK's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. ANIK: 73.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANIK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -171.43  Med: 22.87 Max: 222.6
Current: 73.04
-171.43
222.6
Revenue Growth (3Y)(%) 13.70
ANIK's Revenue Growth (3Y)(%) is ranked higher than
71% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ANIK: 13.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANIK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.5  Med: 7.50 Max: 26.7
Current: 13.7
-4.5
26.7
EBITDA Growth (3Y)(%) 49.00
ANIK's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ANIK: 49.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANIK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.1  Med: 38.80 Max: 95.7
Current: 49
-65.1
95.7
EPS Growth (3Y)(%) 59.40
ANIK's EPS Growth (3Y)(%) is ranked higher than
95% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ANIK: 59.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANIK' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.3  Med: 24.70 Max: 72.4
Current: 59.4
-64.3
72.4
» ANIK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ANIK Guru Trades in Q2 2014

Joel Greenblatt 235,399 sh (New)
Chuck Royce 1,300 sh (unchged)
Jim Simons 367,400 sh (-16.95%)
Paul Tudor Jones 6,759 sh (-36.55%)
» More
Q3 2014

ANIK Guru Trades in Q3 2014

Joel Greenblatt 375,753 sh (+59.62%)
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
Jim Simons 270,600 sh (-26.35%)
» More
Q4 2014

ANIK Guru Trades in Q4 2014

Joel Greenblatt 347,187 sh (-7.60%)
Jim Simons 212,800 sh (-21.36%)
» More
Q1 2015

ANIK Guru Trades in Q1 2015

John Burbank 10,047 sh (New)
Joel Greenblatt 278,578 sh (-19.76%)
Jim Simons 112,500 sh (-47.13%)
» More
» Details

Insider Trades

Latest Guru Trades with ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.07
ANIK's P/E(ttm) is ranked higher than
75% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ANIK: 21.07 )
Ranked among companies with meaningful P/E(ttm) only.
ANIK' s 10-Year P/E(ttm) Range
Min: 8.66  Med: 20.00 Max: 46.11
Current: 21.07
8.66
46.11
Forward P/E 24.69
ANIK's Forward P/E is ranked higher than
53% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. ANIK: 24.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.70
ANIK's PE(NRI) is ranked higher than
76% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. ANIK: 19.70 )
Ranked among companies with meaningful PE(NRI) only.
ANIK' s 10-Year PE(NRI) Range
Min: 8.57  Med: 20.00 Max: 46.32
Current: 19.7
8.57
46.32
P/B 3.09
ANIK's P/B is ranked higher than
70% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ANIK: 3.09 )
Ranked among companies with meaningful P/B only.
ANIK' s 10-Year P/B Range
Min: 0.58  Med: 2.35 Max: 5.46
Current: 3.09
0.58
5.46
P/S 6.64
ANIK's P/S is ranked higher than
68% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. ANIK: 6.64 )
Ranked among companies with meaningful P/S only.
ANIK' s 10-Year P/S Range
Min: 1  Med: 3.82 Max: 9.2
Current: 6.64
1
9.2
PFCF 19.48
ANIK's PFCF is ranked higher than
78% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. ANIK: 19.48 )
Ranked among companies with meaningful PFCF only.
ANIK' s 10-Year PFCF Range
Min: 4.25  Med: 19.62 Max: 1445
Current: 19.48
4.25
1445
POCF 18.57
ANIK's POCF is ranked higher than
77% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. ANIK: 18.57 )
Ranked among companies with meaningful POCF only.
ANIK' s 10-Year POCF Range
Min: 4.19  Med: 18.75 Max: 429.5
Current: 18.57
4.19
429.5
EV-to-EBIT 10.00
ANIK's EV-to-EBIT is ranked higher than
83% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. ANIK: 10.00 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIK' s 10-Year EV-to-EBIT Range
Min: 1.8  Med: 10.90 Max: 37.9
Current: 10
1.8
37.9
PEG 0.42
ANIK's PEG is ranked higher than
96% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. ANIK: 0.42 )
Ranked among companies with meaningful PEG only.
ANIK' s 10-Year PEG Range
Min: 0.28  Med: 0.62 Max: 10.15
Current: 0.42
0.28
10.15
Shiller P/E 35.34
ANIK's Shiller P/E is ranked higher than
71% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. ANIK: 35.34 )
Ranked among companies with meaningful Shiller P/E only.
ANIK' s 10-Year Shiller P/E Range
Min: 6.1  Med: 27.65 Max: 178.13
Current: 35.34
6.1
178.13
Current Ratio 23.70
ANIK's Current Ratio is ranked higher than
92% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. ANIK: 23.70 )
Ranked among companies with meaningful Current Ratio only.
ANIK' s 10-Year Current Ratio Range
Min: 2.84  Med: 6.20 Max: 23.7
Current: 23.7
2.84
23.7
Quick Ratio 21.67
ANIK's Quick Ratio is ranked higher than
92% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ANIK: 21.67 )
Ranked among companies with meaningful Quick Ratio only.
ANIK' s 10-Year Quick Ratio Range
Min: 1.21  Med: 5.43 Max: 21.67
Current: 21.67
1.21
21.67
Days Inventory 228.44
ANIK's Days Inventory is ranked lower than
76% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. ANIK: 228.44 )
Ranked among companies with meaningful Days Inventory only.
ANIK' s 10-Year Days Inventory Range
Min: 98.12  Med: 150.32 Max: 278.55
Current: 228.44
98.12
278.55
Days Sales Outstanding 67.15
ANIK's Days Sales Outstanding is ranked lower than
54% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ANIK: 67.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIK' s 10-Year Days Sales Outstanding Range
Min: 21.47  Med: 56.62 Max: 109.78
Current: 67.15
21.47
109.78

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.68
ANIK's Price/Net Cash is ranked higher than
66% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. ANIK: 5.68 )
Ranked among companies with meaningful Price/Net Cash only.
ANIK' s 10-Year Price/Net Cash Range
Min: 0.48  Med: 8.20 Max: 79.94
Current: 5.68
0.48
79.94
Price/Net Current Asset Value 4.21
ANIK's Price/Net Current Asset Value is ranked higher than
75% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. ANIK: 4.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANIK' s 10-Year Price/Net Current Asset Value Range
Min: 0.34  Med: 4.65 Max: 40.16
Current: 4.21
0.34
40.16
Price/Tangible Book 3.40
ANIK's Price/Tangible Book is ranked higher than
70% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ANIK: 3.40 )
Ranked among companies with meaningful Price/Tangible Book only.
ANIK' s 10-Year Price/Tangible Book Range
Min: 0.29  Med: 2.69 Max: 13.2
Current: 3.4
0.29
13.2
Price/Projected FCF 1.51
ANIK's Price/Projected FCF is ranked higher than
87% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ANIK: 1.51 )
Ranked among companies with meaningful Price/Projected FCF only.
ANIK' s 10-Year Price/Projected FCF Range
Min: 0.48  Med: 2.12 Max: 57.5
Current: 1.51
0.48
57.5
Price/Median PS Value 1.67
ANIK's Price/Median PS Value is ranked lower than
64% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ANIK: 1.67 )
Ranked among companies with meaningful Price/Median PS Value only.
ANIK' s 10-Year Price/Median PS Value Range
Min: 0.13  Med: 0.86 Max: 2.49
Current: 1.67
0.13
2.49
Price/Peter Lynch Fair Value 0.83
ANIK's Price/Peter Lynch Fair Value is ranked higher than
90% of the 49 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ANIK: 0.83 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ANIK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.37  Med: 0.87 Max: 5.53
Current: 0.83
0.37
5.53
Price/Graham Number 1.76
ANIK's Price/Graham Number is ranked higher than
79% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. ANIK: 1.76 )
Ranked among companies with meaningful Price/Graham Number only.
ANIK' s 10-Year Price/Graham Number Range
Min: 0.5  Med: 1.68 Max: 8.23
Current: 1.76
0.5
8.23
Earnings Yield (Greenblatt) (%) 9.97
ANIK's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ANIK: 9.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANIK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.6  Med: 9.20 Max: 56.4
Current: 9.97
2.6
56.4
Forward Rate of Return (Yacktman) (%) 53.57
ANIK's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. ANIK: 53.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANIK' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -11.2  Med: 4.10 Max: 55.9
Current: 53.57
-11.2
55.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AKP.Germany,
Anika Therapeutics Inc was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through its subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents,therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are Merogel, a woven fleece nasal
» More Articles for ANIK

Headlines

Articles On GuruFocus.com
Four Stocks With Growing EPS Near Their 52-Week Lows - Part II Jul 02 2015 
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
comment on ANIK Apr 29 2012 
Not bad for a small Aug 06 2011 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Nov 03 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Edited Transcript of ANIK earnings conference call or presentation 30-Jul-15 1:00pm GMT Jul 31 2015
Anika Therapeutics Inc Earnings Call scheduled for 9:00 am ET today Jul 30 2015
Anika posts 2Q profit Jul 29 2015
Anika posts 2Q profit Jul 29 2015
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015
Anika Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline... Jul 29 2015
4:27 pm Anika Therapeutics beats by $0.17, beats on revs (limited coverage) Jul 29 2015
Anika Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline... Jul 29 2015
Q2 2015 Anika Therapeutics Inc Earnings Release - After Market Close Jul 29 2015
Anika Therapeutics to Issue Second Quarter 2015 Financial Results and Business Highlights on... Jul 15 2015
Anika Therapeutics to Issue Second Quarter 2015 Financial Results and Business Highlights on... Jul 15 2015
Bedford biotech sees promising results from arthritis injection study Jul 10 2015
Anika Therapeutics Announces Positive Results from Follow-up Study Evaluating Safety of a Repeat... Jul 09 2015
Anika Therapeutics Announces Positive Results from Follow-up Study Evaluating Safety of a Repeat... Jul 09 2015
Hyaluronic acid viscosupplementation market news: Anika Therapeutics reports positive results from... Jul 08 2015
Anika Therapeutics Files Investigational Device Exemption to Initiate Phase III Study to Expand... Jun 23 2015
Anika Therapeutics Files Investigational Device Exemption to Initiate Phase III Study to Expand... Jun 23 2015
Anika Therapeutics Announces Strategic Collaboration with the Institute for Applied Life Sciences... Jun 17 2015
Anika Therapeutics Announces Strategic Collaboration with the Institute for Applied Life Sciences... Jun 17 2015
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK